

BAGER,ARWA

DOB: 03/31/1981  
Sex: F  
Phone: (305) 788-5319  
Patient ID: 69797

Age: 41  
Fasting:

Specimen: MR797267K  
Requisition: 1955200  
Lab Reference ID: 575436  
Report Status: FINAL / SEE REPORT

Collected: 07/06/2022 10:45  
Received: 07/06/2022 23:42  
Reported: 07/11/2022 22:45

Client #: 11046  
EISERMANN,JUERGEN  
S FL INST FOR REPROD MED  
7300 SW 62ND PL FL 4  
SOUTH MIAMI, FL 33143-4800  
Phone: (305) 662-7901 ext. 7718  
Fax: (305) 662-7910

**HIV 1/2 ANTIGEN/ANTIBODY,FOURTH GENERATION W/RFL****HIV 1/2 ANTIGEN/ANTIBODY,FOURTH GENERATION W/RFL**

Analyte	Value
<b>HIV AG/AB, 4TH GEN</b>	<b>NON-REACTIVE</b> Reference Range: NON-REACTIVE
HIV-1 antigen and HIV-1/HIV-2 antibodies were not detected. There is no laboratory evidence of HIV infection.	

PLEASE NOTE: This information has been disclosed to you from records whose confidentiality may be protected by state law. If your state requires such protection, then the state law prohibits you from making any further disclosure of the information without the specific written consent of the person to whom it pertains, or as otherwise permitted by law. A general authorization for the release of medical or other information is NOT sufficient for this purpose.

**▲ TSH**

Analyte	Value
<b>▲ TSH</b>	<b>5.05 H</b> mIU/L
Reference Range	
> or = 20 Years 0.40-4.50	
Pregnancy Ranges	
First trimester	0.26-2.66
Second trimester	0.55-2.73
Third trimester	0.43-2.91

**VITAMIN D,25-OH,TOTAL,IA**

Analyte	Value
<b>VITAMIN D,25-OH,TOTAL,IA</b>	<b>64</b> Reference Range: 30-100 ng/mL
Vitamin D Status	25-OH Vitamin D:
Deficiency:	<20 ng/mL
Insufficiency:	20 - 29 ng/mL
Optimal:	> or = 30 ng/mL
For 25-OH Vitamin D testing on patients on D2-supplementation and patients for whom quantitation of D2 and D3 fractions is required, the QuestAssured(TM) 25-OH VIT D, (D2,D3), LC/MS/MS is recommended: order code 92888 (patients >2yrs).	

**COMMENT**

See Note 1

Note 1

For additional information, please refer to <http://education.QuestDiagnostics.com/faq/FAQ199> (This link is being provided for informational/ educational purposes only.)

**CHLAMYDIA TRACHOMATIS AB (IGG,IGA,IGM)**

Analyte	Value
BAGER,ARWA (MR797267K)	1 / 4

11/10/25

<b>C. TRACHOMATIS AB (IGG)</b>	<b>&lt;1:64</b>	Reference Range: <1:64 titer
<b>C. TRACHOMATIS AB (IGA)</b>	<b>&lt;1:16</b>	Reference Range: <1:16 titer
<b>C. TRACHOMATIS AB (IGM)</b>	<b>&lt;1:10</b>	Reference Range: <1:10 titer

#### INTERPRETATION

see note

Antibody Not Detected

Reference Range:

IgM <1:10

IgG <1:64

IgA <1:16

The immunofluorescent detection of specific antibodies to Chlamydia trachomatis may be complicated by crossreactive antibodies, non-specific antibody stimulation, or past exposure to similar organisms such as Chlamydia pneumoniae and C. psittaci. IgM titers of 1:10 or greater usually indicate recent infection and any IgG titer may indicate past exposure. IgA is typically present at low titers during primary infection, but may be elevated in recurrent exposures or in chronic infection.

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute, Chantilly, VA. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

## ABO GROUP AND RH TYPE

Analyte	Value
<b>ABO GROUP</b>	<b>A</b>
<b>RH TYPE</b>	<b>RH(D) POSITIVE</b>

#### COMMENT

For additional information, please refer to <http://education.QuestDiagnostics.com/faq/FAQ111> (This link is being provided for informational/educational purposes only.)

## HEMOGLOBIN A1c

Analyte	Value
<b>HEMOGLOBIN A1c</b>	<b>5.4</b> Reference Range: <5.7 % of total Hgb

For the purpose of screening for the presence of diabetes:

<5.7% Consistent with the absence of diabetes  
5.7-6.4% Consistent with increased risk for diabetes (prediabetes)  
> or =6.5% Consistent with diabetes

This assay result is consistent with a decreased risk of diabetes.

Currently, no consensus exists regarding use of hemoglobin A1c for diagnosis of diabetes in children.

According to American Diabetes Association (ADA) guidelines, hemoglobin A1c <7.0% represents optimal control in non-pregnant diabetic patients. Different metrics may apply to specific patient populations. Standards of Medical Care in Diabetes(ADA).

## T4 (THYROXINE), TOTAL

Analyte	Value
T4 (THYROXINE), TOTAL	11.4 Reference Range: 5.1-11.9 mcg/dL

## T4, FREE

Analyte	Value
T4, FREE	1.5 Reference Range: 0.8-1.8 ng/dL

## THYROGLOBULIN ANTIBODIES

Analyte	Value
THYROGLOBULIN ANTIBODIES	<1 Reference Range: < or = 1 IU/mL

## THYROID PEROXIDASE ANTIBODIES

Analyte	Value
THYROID PEROXIDASE ANTIBODIES	<1 Reference Range: <9 IU/mL

## HEPATITIS B SURFACE ANTIGEN W/REFL CONFIRM

Analyte	Value
HEPATITIS B SURFACE ANTIGEN	NON-REACTIVE Reference Range: NON-REACTIVE

## HEPATITIS C AB W/REFL TO HCV RNA, QN, PCR

Analyte	Value
HEPATITIS C ANTIBODY	NON-REACTIVE Reference Range: NON-REACTIVE

**INDEX** 0.01 Reference Range: <1.00

HCV antibody was non-reactive. There is no laboratory evidence of HCV infection.

In most cases, no further action is required. However, if recent HCV exposure is suspected, a test for HCV RNA (test code 35645) is suggested.

For additional information please refer to <http://education.questdiagnostics.com/faq/FAQ22v1> (This link is being provided for informational/ educational purposes only.)

## RUBELLA AB (IGG), IMMUNE STATUS

Analyte	Value
RUBELLA AB (IGG), IMMUNE STATUS	6.32 Index

Index	Interpretation
-----	-----
<0.90	Not consistent with immunity
0.90-0.99	Equivocal
> or = 1.00	Consistent with immunity

The presence of rubella IgG antibody suggests immunization or past or current infection with rubella virus.

## VARICELLA ZOSTER VIRUS ANTIBODY (IGG)

Analyte	Value
---------	-------

**VARICELLA ZOSTER VIRUS ANTIBODY (IGG)****1557.00** index

Index	Interpretation
<135.00	Negative - Antibody not detected
135.00 - 164.99	Equivocal
> or = 165.00	Positive - Antibody detected

A positive result indicates that the patient has antibody to VZV but does not differentiate between an active or past infection. The clinical diagnosis must be interpreted in conjunction with the clinical signs and symptoms of the patient. This assay reliably measures immunity due to previous infection but may not be sensitive enough to detect antibodies induced by vaccination. Thus, a negative result in a vaccinated individual does not necessarily indicate susceptibility to VZV infection. A more sensitive test for vaccination-induced immunity is Varicella Zoster Virus Antibody Immunity Screen, ACIF.

**PROLACTIN**

Analyte	Value
<b>PROLACTIN</b>	<b>5.2</b> ng/mL
Reference Range	
Females	
Non-pregnant	3.0-30.0
Pregnant	10.0-209.0
Postmenopausal	2.0-20.0

**RPR (DX) W/REFL TITER AND CONFIRMATORY TESTING**

Analyte	Value
<b>RPR (DX) W/REFL TITER AND CONFIRMATORY TESTING</b>	<b>NON-REACTIVE</b> Reference Range: NON-REACTIVE

**Performing Sites**

AMD Quest Diagnostics/Nichols Chantilly-Chantilly VA, 14225 Newbrook Dr, Chantilly, VA 20151-2228 Laboratory Director: Patrick W Mason M.D., PhD  
MI Quest Diagnostics-Miami, 10200 Commerce Pkwy, Miramar, FL 33025-3938 Laboratory Director: Julie L Friedman, MD

**Key**

 Priority Out of Range  Out of Range

These results have been sent to the person who ordered the tests. Your receipt of these results should not be viewed as medical advice and is not meant to replace discussion with your doctor or other healthcare professional.

Quest, Quest Diagnostics, the associated logo, Nichols Institute, Interactive Insights and all associated Quest Diagnostics marks are the registered trademarks of Quest Diagnostics. All third party marks - '®' and '™' - are the property of their respective owners. Privacy policy can be found at: <http://questdiagnostics.com/home/privacy-policy/online-privacy.html>. © 2022 Quest Diagnostics Incorporated. All rights reserved.

